Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion; FDA approves AstraZeneca, Ionis treatment for rare nerve disease

Taking stock of the drug industry, from the lab to the medicine chest

December 22, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Bristol Myers Squibb STAT+ | Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion The centerpiece of the transaction, which values Karuna at $330 per share, is a drug called KarXT to treat schizophrenia. By Adam Feuerstein STAT+ | FDA approves AstraZeneca, Ionis treatment for rare nerve disease The drug treats a genetic disorder called ATTR-PN, in which a buildup of toxic bodily proteins progressively damages patients' peripheral nerves. By Damian Garde Listen: 2023 in review, CEO report cards, and a look at the year ahead In our last episode of 2023, we look back on the biggest stories of the year and discuss the best and worst CEOs in the biotech industry. By Damian Garde and Allison DeAngelis and Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser